Overview
RenovoRx, Inc. (NASDAQ: RNXT) reported insider purchases by Chief Financial Officer Mark Voll in transactions dated March 20, 2026. According to the filing, Voll acquired 97,200 shares of common stock in a purchase that listed no per-share price and stated a total value of $0. In the same set of transactions, Voll also purchased 48,600 warrants exercisable for common stock at an exercise price of $1.9326.
Terms of the warrants and purchase structure
The warrants acquired on March 20, 2026 are exercisable immediately and carry an expiration date of March 30, 2029. They also include a conditional expiration provision - they will expire 30 days after the company reports $1.5 million in product sales revenue for any calendar quarter. The filing states these securities were purchased in a private placement on March 20, 2026 for an aggregate of $100,000.
Market context and recent trading
At the time of the disclosure, RNXT was trading at $1.08 per share. The company’s stock is up 28.56% year-to-date. With earnings scheduled in just 5 days, the timing of the insider purchases and the financing activity coincides with an upcoming corporate disclosure.
Company financing and analyst coverage
RenovoRx has announced execution of securities purchase agreements with institutional investors aimed at raising approximately $10 million through a private placement. The financing initiative was led by life science institutional investors and included participation from members of the company’s executive management team and board of directors. Konik Capital Partners, LLC, a division of T.R. Winston & Company, acted as the sole placement agent for the transaction. Separately, Jones Trading initiated coverage on RenovoRx with a Buy rating and an $8.00 price target.
What the filings show
- Mark Voll purchased 97,200 shares of common stock - a purchase with no price listed and a total value of $0, per the filing.
- Voll also purchased 48,600 warrants exercisable at $1.9326; these are exercisable immediately and expire March 30, 2029, or 30 days after the company reports $1.5 million in product sales revenue for any calendar quarter.
- Both the shares and warrants were part of a private placement on March 20, 2026 for an aggregate of $100,000.
Near-term calendar
The company has earnings scheduled in 5 days, a near-term event noted in the disclosure. The financing activity and the insider transactions occurred ahead of that scheduled report.
Takeaway
The filings document insider purchases by the company’s CFO and confirm a concurrent private placement effort intended to raise roughly $10 million, backed by life science institutional investors with the company’s management and board participating. The filing also records fresh analyst coverage assigning a Buy rating with an $8.00 price target. Beyond the headline transactions, the warrants include an exercise price, an immediate exercisability provision, and a revenue-triggered expiration clause that links potential conversion timing to product sales milestones.